This is of particular interest, considering that it is known that the enhancement of cholinergic neurotransmission through cholinesterase inhibitors is the leading therapeutic option for treating the cognitive and behavioral symptoms of the early and late stages of AD [25]. Here, BCHE is linked to Alzheimer disease.